The article argues that while Moderna (MRNA) recently surged 63% year-to-date following a Q1 revenue triple, its long-term fundamentals remain weak. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, with management projecting only up to 10% growth for 2026 off this depressed base. Approximately 80% of Q1 2026 sales originated outside the U.S., and the company's franchise is still heavily reliant on a single COVID product.
Moderna faces significant financial headwinds, with year-end cash projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by the end of 2026. The company drew $600 million on a credit facility while Q1 GAAP net loss widened to $1.34 billion. There are no dividends or buybacks, and upcoming catalysts like the August 5, 2026 flu vaccine PDUFA and melanoma readouts are described as binary events rather than steady earnings drivers.
In contrast, the author recommends Gilead Sciences (GILD) as a superior long-term holding for retirement portfolios. Gilead is characterized as a cash-flow machine with an HIV franchise that grew 10% to $5.03 billion in Q1 2026, driven largely by Biktarvy which generated $3.36 billion alone. The company trades at a forward earnings multiple of 15 and offers a 2.46% dividend yield with a market cap near $162 billion.
Gilead provides real shareholder returns through a declared quarterly dividend payable June 29, 2026, and significant stock repurchases totaling $419 million in Q1 alone against a $6.0 billion buyback authorization. The company's headline EPS loss is attributed to roughly $11.5 billion in one-time IPR&D charges from recent acquisitions rather than operational issues. With a strong pipeline including four potential launches and five Phase 3 updates anticipated in 2026, Gilead can fund its growth from operating cash flow.
📉 Moderna 2025 revenue collapsed 40% to $1.94 billion.
💸 Moderna cash projected to fall to $4.5B–$5.0B by 2026.
📈 Gilead Q1 HIV revenue hit $5.03B driven by Biktarvy.
🛡️ Gilead's Biktarvy patent extended to April 2036.
📊 Gilead trades at 15x forward earnings vs Moderna's depressed base.
📉 Moderna's full-year 2025 revenue collapsed to $1.94 billion, representing a roughly 40% drop from the prior year.
💸 Moderna's year-end cash is projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by year-end 2026.
📈 Gilead Sciences generated Q1 2026 HIV franchise revenue of $5.03 billion, a 10% increase driven by Biktarvy sales of $3.36 billion.
💰 Gilead declared a quarterly dividend of $0.82 payable June 29, 2026, and repurchased $419 million of stock in Q1 alone.
🔬 Moderna's upcoming catalysts are binary events like the August 5, 2026 flu vaccine PDUFA rather than steady earnings drivers.
🛡️ Gilead's patent protection on Biktarvy was extended to April 2036, ensuring no major loss of exclusivity for a full decade.
📊 Gilead trades at a forward earnings multiple of 15 with a market cap near $162 billion compared to Moderna's depressed base.
🧬 Gilead's headline EPS loss guidance is an artifact of roughly $11.5 billion in one-time IPR&D charges from acquisitions like Arcellx and Ouro Medicines.
Bullish Signals
- Q1 free cash flow hit $2.427 billion, up 237% YoY.
- HIV franchise grew 10% to $5.03 billion in Q1 2026.
- Offers 2.46% dividend yield and $6.0 billion buyback authorization.
- Non-GAAP gross margin expanded 200 bps to 87.5%.
- Strong pipeline with four launches and five Phase 3 updates in 2026.
Risk Factors
- Single COVID product creates concentration risk outside U.S.
- No dividend or buybacks while drawing on credit facility.
- Upcoming catalysts are binary events with high uncertainty.
- $11.5B one-time charges impact Gilead's reported profitability.
Bullish Signals
- Gilead Sciences is generating real free cash flow, with Q1 free cash flow hitting $2.427 billion, up 237.08% year over year.
- Gilead's HIV franchise grew 10% to $5.03 billion in Q1 2026, demonstrating strong recurring revenue potential.
- Gilead offers tangible shareholder returns via a 2.46% dividend yield and a $6.0 billion buyback authorization.
- Gilead's non-GAAP product gross margin expanded 200 basis points to 87.5%, indicating operational efficiency.
- Gilead possesses a strong pipeline with up to four potential launches and five Phase 3 updates anticipated in 2026.
- Moderna's recent stock surge is attributed to a prior year disaster rather than improved fundamentals, suggesting the bounce may be temporary.
Risk Factors
- Moderna's entire franchise is effectively a single COVID product, creating concentration risk outside the U.S. market.
- Moderna has no dividend and no buyback program while actively drawing on its credit facility to manage liquidity.
- Moderna's upcoming catalysts are binary events with high uncertainty rather than predictable earnings drivers.
- Gilead's headline EPS loss guidance is driven by roughly $11.5 billion in one-time IPR&D charges from acquisitions, which may impact reported profitability.
Moderna (NASDAQ:MRNA) was ranked number one on TIME's 2026 list of the World's Most Impactful Companies, a distinction based on the Upright Project's Net Impact Model which evaluates net-positive contributions across Society, Knowledge, Health, and Environment. The recognition highlights Moderna's status as a pioneer in mRNA technology and its commitment to delivering meaningful benefits for patients and society through innovative medicines addressing unmet needs in infectious diseases, oncology, and rare diseases.
In 2026, the company achieved a significant regulatory milestone with European approval for mCOMBRIAX, its fourth product and first combination vaccine targeting both flu and COVID. This expansion of its respiratory portfolio supports broader pandemic preparedness efforts. Additionally, Moderna deepened long-term strategic partnerships with the UK, Canada, and Australia to expand manufacturing capacity and minimize response times for future pandemics.
Beyond commercial products, Moderna highlighted its commitment to global health equity through its mRNA Access program, which has grown to include 35 institutions worldwide since its 2022 launch. The company also marked the fourth anniversary of its Charitable Foundation and published its fourth annual Impacting Human Health Report, reinforcing its focus on societal impact alongside scientific advancement.
🏆 Ranked #1 on TIME's 2026 World's Most Impactful Companies list.
💉 European approval granted in 2026 for mCOMBRIAX flu/COVID vaccine.
🤝 Expanded partnerships with UK, Canada, and Australia for pandemic readiness.
🔬 mRNA Access program now includes 35 global research institutions.
📅 Celebrated fourth anniversary of Charitable Foundation and released annual report.
🏆 Moderna ranked #1 on TIME's 2026 World's Most Impactful Companies list based on the Upright Project's Net Impact Model.
💉 European regulatory approval granted in 2026 for mCOMBRIAX, a flu plus COVID combination vaccine.
🤝 Strategic partnerships expanded with the UK, Canada, and Australia to boost pandemic preparedness and manufacturing capacity.
🔬 mRNA Access program now includes 35 institutions globally researching vaccines for emerging infectious diseases.
📅 Moderna celebrated the fourth anniversary of its Charitable Foundation and released its fourth annual Impacting Human Health Report.
🧬 CEO Stéphane Bancel emphasized the team's dedication to advancing mRNA science for patients and communities worldwide.
Bullish Signals
- Moderna ranked #1 on TIME's 2026 list.
- EU approved mCOMBRIAX flu/COVID single-shot vaccine.
- Alliances with UK, Canada, Australia show confidence.
- mRNA Access program grew to 35 institutions.
Bullish Signals
- Moderna secured the top spot on TIME's prestigious 2026 list, validating its leadership in mRNA technology and societal impact.
- The European approval of mCOMBRIAX expands Moderna's product portfolio with a novel single-shot combination vaccine for flu and COVID.
- Strategic alliances with major nations like the UK, Canada, and Australia demonstrate strong government confidence in Moderna's pandemic readiness capabilities.
- The growth of the mRNA Access program to 35 institutions showcases the company's success in fostering open scientific collaboration for neglected diseases.
Moderna faces significant commercial headwinds as mRNA vaccines struggle in post-pandemic markets, prompting a strong sell recommendation based on underperformance against traditional competitors. RSV and flu mRNA candidates are criticized for lower durability, higher side effects, and weak market uptake, resulting in program cuts and strategic pivots by the company. While combination therapies like mCOMBRIAX show regulatory progress, commercial success remains uncertain due to persistent consumer vaccine fatigue and lack of immediate financial viability in current indications.
The article highlights that personalized cancer vaccines, while potentially leveraging mRNA technology's speed advantages, face substantial hurdles including margin constraints, scalability issues, and regulatory complexities that limit their near-term financial upside for Moderna. The author, a Chemistry PhD with biotech investment experience, notes these challenges stem from the technology being viable primarily in pandemic-level scenarios rather than routine annual immunization markets where competition is intensifying from established protein-based vaccine makers.
The analysis concludes that without new breakthroughs or regulatory fast-tracking that overcomes current limitations regarding durability and adverse events, Moderna's revenue trajectory looks weaker than peers, particularly given the expiration of patent-protected revenue streams that once drove stock valuations. The investment thesis suggests investors should be cautious of capital allocation risks as management attempts to pivot from pandemic-era products to harder-to-develop treatments in a crowded therapeutic landscape without guaranteed commercial returns.
📉 mRNA vaccines struggle with lower durability, side effects, and weak post-pandemic market uptake.
✂️ Commercial setbacks force program cuts and a strategic pivot away from current vaccine portfolios.
⚠️ Analysts rate Moderna "Strong Sell" due to intense competition and uncertain financial upside.
🔬 Traditional competitors outperform in key segments, weakening Moderna's overall competitive position today.
📉 Moderna (MRNA) faces significant commercial setbacks as its mRNA vaccines underperform compared to traditional competitors in post-pandemic markets.
💉 RSV and flu mRNA vaccines are struggling due to lower durability, higher side effects, and weak market uptake.
✂️ These commercial challenges have led to program cuts and a need for strategic pivots within Moderna's vaccine portfolio.
🤝 Combination mRNA vaccines such as mCOMBRIAX show regulatory progress, but commercial success remains uncertain due to ongoing vaccine fatigue.
🧬 Personalized cancer vaccines utilizing mRNA technology may benefit from speed, yet face hurdles in margins, scalability, and regulation that limit financial upside.
📄 The analysis is based on the premise that mRNA vaccines may only be viable in scenarios similar to the recent COVID-19 pandemic conditions.
🏆 Traditional competitors are outperforming Moderna in current market segments, weakening its competitive position in key therapeutic areas.
📊 Previous investment coverage from 2024 highlighted risks regarding the uncertain future of mRNA vaccines in a post-pandemic world.
🔬 The author identifies as a Chemistry PhD and scientist with expertise in biotech data to inform their investment thesis.
⚠️ Analysts recommend a "Strong Sell" rating for Moderna stock given these negative commercial trends and uncertainties.
📅 Article published on May 12, 2026, reflecting current market conditions and sentiment as of that date.
🛡️ Standard disclosures indicate the author holds no position in Moderna stock and receives no compensation beyond Seeking Alpha affiliation.
⚖️ Seeking Alpha's standard disclaimer notes that past performance does not guarantee future results and that this is not formal investment advice.
Bullish Signals
- Combination mRNA vaccines like mCOMBRIAX have achieved regulatory progress, signaling potential pathway for future development.
- Personalized cancer vaccines leverage the inherent speed of mRNA technology, offering a distinct advantage for R&D efficiency.
Risk Factors
- MRNA underperforms in post-pandemic markets.
- RSV & flu mRNA vaccines have durability issues.
- mCOMBRIAX faces commercial uncertainty.
- Personalized cancer vaccines face scalability hurdles.
Bullish Signals
- Combination mRNA vaccines like mCOMBRIAX have achieved regulatory progress, signaling potential pathway for future development.
- Personalized cancer vaccines leverage the inherent speed of mRNA technology, offering a distinct advantage for R&D efficiency.
Risk Factors
- Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets.
- RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and strategic pivots.
- Combination mRNA vaccines like mCOMBRIAX offer regulatory progress but commercial success remains uncertain amid persistent vaccine fatigue.
- Personalized cancer vaccines may leverage mRNA speed but face margin, scalability, and regulatory hurdles, limiting their financial upside for MRNA.
Moderna (MRNA) shares recently surged, gaining up to 22% over two days, driven by investor speculation regarding a hantavirus outbreak linked to an Atlantic cruise ship. The incident resulted in three fatalities and sparked international headlines, triggering market memory from the 2020 pandemic era despite the World Health Organization noting that human-to-human transmission remains rare.
Moderna is positioned as a primary beneficiary due to its existing early-stage research into hantavirus vaccines and collaborations with the U.S. Army and Korea University. However, the company explicitly describes these efforts as ongoing, and there is currently no approved vaccine for hantavirus available on the market.
Analysts warn of a significant valuation disconnect between the stock's rally and its fundamental reality. While Moderna's stock price has risen sharply over the past 12 months, a localized outbreak is unlikely to generate the multibillion-dollar revenue streams seen during the COVID-19 era. The article suggests that unless clinical trial timelines accelerate significantly, this rally may prove fleeting as investors buy the headline rather than the substance.
📈 Moderna stock surged 22% after hantavirus cruise ship deaths.
🔬 Company holds early-stage vaccine research with U.S. Army and Korea.
⚠️ No approved hantavirus vaccine exists; Moderna's efforts remain ongoing.
💰 Rally driven by headlines, not comparable multibillion-dollar revenue potential.
📉 Stock remains below $350 pandemic peak despite recent gains.
📈 Moderna stock surged up to 22% in two days following news of a deadly hantavirus cluster on an Atlantic cruise ship.
🦠 The outbreak involved three fatalities and sparked international headlines, causing investors to recall the market dynamics of the 2020 pandemic.
🔬 Moderna holds early-stage research collaborations with the U.S. Army and Korea University for a hantavirus vaccine.
⚠️ There is currently no approved vaccine for hantavirus, and Moderna describes its efforts as 'early-stage and ongoing'.
💰 Investors are buying the headline, but the localized outbreak is unlikely to generate multibillion-dollar revenue streams comparable to COVID-19.
📉 The article warns that without significant acceleration in clinical trial timelines, the current rally may be fleeting.
📊 Moderna's stock has been trading below its pandemic peak of over $350 for nearly two years prior to this recent surge.
Bullish Signals
- Natural first pick for hantavirus due to strong research.
- Credible mRNA platform with unique early-stage data vs. peers.
Risk Factors
- No product available; efforts are early-stage and ongoing.
- Stock price rose sharply without immediate revenue potential.
- Localized outbreaks unlikely to match COVID-19 era revenue.
- Rally may be fleeting if trials do not accelerate.
Bullish Signals
- Moderna is identified as the 'natural first place to look' for hantavirus plays due to its long-standing research and existing collaborations with the U.S. Army and Korea University.
- The company possesses a credible mRNA platform specifically positioned for this rodent-borne pathogen, distinguishing it from competitors without such early-stage data.
Risk Factors
- Moderna explicitly describes its hantavirus vaccine efforts as 'early-stage and ongoing,' meaning no product is currently available for sale.
- The article highlights a 'classic valuation disconnect' where the stock price has risen sharply despite the lack of immediate revenue potential from this specific threat.
- Analysts caution that a localized outbreak will likely not generate the massive revenue streams seen during the COVID-19 era, limiting the fundamental upside.
- The rally is described as potentially 'fleeting' if clinical trial timelines do not accelerate significantly to meet investor expectations.
Simply Wall St analyzes Moderna (MRNA), noting a recent surge with a 51.4% year-to-date return and a current price of $46.71. The article questions whether the market has overvalued the stock, citing a DCF model that projects significant future cash outflows until 2030, resulting in an intrinsic value of roughly $3.90 per share.
This valuation suggests Moderna is significantly overvalued by approximately 1,097% based on discounted cash flow analysis. However, the stock's Price-to-Sales ratio of 8.33x is comparable to industry and peer averages, though it exceeds the platform's proprietary 'Fair Ratio' of 1.56x, indicating potential expense relative to growth expectations.
The article presents two contrasting investment narratives for Moderna. An optimistic view sees a strong balance sheet and a transition period following COVID-19 revenue pullbacks, implying a fair value near $175. Conversely, a cautious narrative views current positives as fully priced in, flags risks like competition and pricing pressure, and suggests the stock is fairly valued at roughly $46.10.
📉 DCF model projects negative cash flows through 2027 with intrinsic value of $3.90.
💰 Moderna trades at 8.33x sales, exceeding the calculated fair ratio of 1.56x.
📈 Stock delivered 91.2% return last year despite weaker long-term historical performance.
🧠 Optimistic view cites strong balance sheet and pipeline with potential fair value of $175.
⚠️ Cautious view notes risks around vaccine demand and regulatory scrutiny near current price.
📉 DCF Analysis: A two-stage free cash flow model projects negative cash flows through 2027, implying an intrinsic value of $3.90 versus the current price of $46.71.
💰 Valuation Metrics: Moderna trades at a Price-to-Sales ratio of 8.33x, which aligns with industry peers but exceeds the platform's calculated Fair Ratio of 1.56x.
📈 Recent Performance: The stock has delivered a 91.2% return over the last year and a 51.4% return year-to-date despite weaker long-term historical returns.
🧠 Optimistic Narrative: One investor story frames recent weakness as an overreaction, highlighting a strong balance sheet and a broad mRNA pipeline with a potential fair value of $175.
⚠️ Cautious Narrative: Another perspective views current positives as reflected in the price, citing risks around vaccine demand and regulatory scrutiny with a consensus fair value near $46.10.
🏦 Financial Health: The company is noted for having low debt and a balance sheet that some analysts view as trading below book value.
Bullish Signals
- 91.2% return over last year.
- 51.4% gain year-to-date.
- Strong balance sheet with low debt.
- Significant mRNA pipeline in trials.
- P/S ratio of 8.33x vs 10.82x industry avg.
Risk Factors
- DCF projects $3.2B outflows in 2026 and $1.5B in 2027.
- Stock overvalued by 1,097% per DCF intrinsic value calculation.
- Current P/S ratio of 8.33x exceeds fair multiple of 1.56x.
- Revenue risks from vaccine demand fluctuations and competition.
- Analyst targets near current price imply limited immediate upside.
Bullish Signals
- Moderna has delivered exceptional recent performance with a 91.2% return over the last year and a 51.4% gain year-to-date.
- The company maintains a strong balance sheet characterized by low debt levels.
- A significant portion of the mRNA pipeline is currently in trials, suggesting future growth potential as earlier investments mature.
- The stock trades below book value according to one optimistic valuation narrative, indicating assets may be undervalued relative to price.
- Moderna's Price-to-Sales ratio of 8.33x is competitive and close to the Biotechs industry average of 10.82x.
Risk Factors
- The Discounted Cash Flow model projects substantial negative free cash flows, estimating outflows of $3.2 billion in 2026 and $1.5 billion in 2027.
- A DCF-based intrinsic value calculation suggests the stock is overvalued by approximately 1,097% compared to current market prices.
- The proprietary Fair Ratio analysis indicates the stock is expensive relative to a calculated fair multiple of 1.56x versus the current 8.33x P/S ratio.
- Risks include potential instability in revenue due to vaccine demand fluctuations, intense competition, and regulatory scrutiny.
- Analyst consensus price targets sit close to the current share price, implying limited immediate upside from a neutral valuation perspective.
Moderna (MRNA) shares rose 4.6% following a post-earnings repricing driven by stronger international vaccine deliveries and reiterated growth frameworks for 2026. The company reported first-quarter 2026 revenue of $389 million, with approximately 80% derived from international markets under long-term partnership agreements. Management highlighted a plan to return to sales growth, targeting up to 10% revenue expansion while reducing GAAP operating expenses in the current year.
The financial results included a first-quarter GAAP net loss of roughly $1.3 billion, or $(3.40) per share, largely due to a non-recurring litigation settlement charge of $0.9 billion recorded in cost of sales and royalties. Excluding this one-time charge, the company emphasized its operational progress and regulatory milestones, including EU approvals for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX, as well as the initiation of a Phase 3 trial for intismeran in high-risk stage 1 NSCLC.
Analyst sentiment remains mixed but active, with several firms lifting price targets following the quarterly release. The median analyst price target stands at $34.0, though individual targets vary significantly, ranging from $30.0 by Jefferies to a bullish $69.0 by Piper Sandler. Institutional ownership saw notable shifts in Q4 2025, with major funds like FMR LLC and Capital World Investors adding substantial positions, while others like UBS reduced theirs.
📈 Moderna shares rose 4.6% on strong Q1 results and pipeline news.
💰 Q1 revenue hit $389M, with 80% from international markets.
⚖️ GAAP loss of $1.3B included a $0.9B litigation settlement charge.
✅ EU approved mNEXSPIKE and flu+COVID combo vaccine mCOMBRIAX.
🔬 Phase 3 trial for intismeran in NSCLC officially initiated.
📈 Moderna shares gained 4.6% as investors reacted positively to Q1 results and pipeline updates.
💰 Q1 2026 revenue reached $389 million, with 80% coming from international markets.
⚖️ GAAP net loss was $1.3 billion due to a $0.9 billion non-recurring litigation settlement charge.
📈 Management reiterated a 2026 plan for up to 10% revenue growth and reduced operating expenses.
✅ EU regulatory approvals were secured for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX.
🔬 A Phase 3 trial for intismeran in high-risk stage 1 NSCLC has officially initiated.
📅 The U.S. PDUFA date for the seasonal flu vaccine candidate is set for August 5, 2026.
🏦 FMR LLC added over 15.7 million shares to its portfolio in Q4 2025.
📉 Insider selling was prominent, with President Stephen Hoge offloading 160,009 shares.
🎯 Analyst price targets range widely from $30.0 to $69.0, with a median of $34.0.
Bullish Signals
- Q1 revenue hit $389M with 80% from international sales.
- Management targets reduced GAAP expenses in 2026.
- EU approved mNEXSPIKE and flu+COVID combo vaccine mCOMBRIAX.
- Phase 3 intismeran trial launched for NSCLC oncology.
- Analysts raised price targets after quarterly earnings release.
- Major investors FMR LLC and Capital World increased holdings.
Risk Factors
- Q1 GAAP net loss of $1.3 billion.
- High insider selling by President and CLO.
- Net institutional outflow: 319 vs 301 investors.
- Two firms issued 'Underperform' ratings.
Bullish Signals
- Moderna reported Q1 revenue of $389 million, demonstrating strong international demand that accounts for roughly 80% of total sales.
- Management has committed to reducing GAAP operating expenses in 2026, excluding the one-time litigation charge, signaling improved operational efficiency.
- The company achieved significant regulatory milestones with EU approvals for mNEXSPIKE and the flu+COVID combo vaccine mCOMBRIAX.
- Initiation of the Phase 3 intismeran trial in high-risk stage 1 NSCLC marks a critical step toward potential oncology revenue diversification.
- Several analysts have lifted price targets following the quarterly release, indicating renewed investor interest in the stock's trajectory.
- Major institutional investors like FMR LLC and Capital World Investors significantly increased their holdings in Q4 2025.
Risk Factors
- The company recorded a substantial GAAP net loss of $1.3 billion in Q1, primarily driven by a $0.9 billion non-recurring litigation settlement charge.
- Insider selling activity has been high over the past six months, with President Stephen Hoge and Chief Legal Officer Shannon Thyme Klinger both executing sales.
- Institutional ownership is mixed, with 319 investors decreasing their positions in the most recent quarter compared to 301 adding shares.
- Analyst ratings are divided, with two firms issuing 'Underperform' ratings from Leerink Partners and B of A Securities.
Moderna (MRNA) is returning to investor focus following its Q1 2026 earnings report, which revealed significant revenue growth driven by vaccine approvals but offset by substantial litigation costs. The company reported quarterly revenue of US$389 million, a sharp increase from US$108 million in the same period a year earlier. However, this financial performance was accompanied by a wider net loss of US$1.343 billion, primarily attributed to ongoing legal expenses. Following these earnings and recent regulatory approvals, the share price has experienced considerable volatility, declining 1.24% over one day and 10.57% over seven days, contributing to a year-to-date drop of 47.02%.
Despite the recent price decline, analysts note that Moderna's stock is trading well below its historical highs and carries a low valuation relative to its assets. The company is currently priced below its book value, a rarity in the biotech sector where debt is often higher. Historical shareholder returns indicate a potential for momentum building after a difficult period, with a one-year total shareholder return of 64.32% compared to long-term declines over three and five years. This discrepancy has prompted analysis suggesting the stock may be undervalued, with some narratives pointing to a fair value as high as US$175 based on pandemic-era cash reserves, pipeline breadth, and future margin potential.
Critics of this bullish valuation outlook point to current market metrics that suggest limited room for error. Moderna trades at a price-to-sales ratio of 9.3x, significantly higher than the estimated fair value ratio of 1x and well above its peers which average around 5.4x. This premium relies heavily on the successful commercialization of its extensive pipeline; setbacks in clinical trials or continued heavy losses could challenge the bullish thesis. The company does maintain a relatively pristine balance sheet with low debt, having reinvested significant profits from its COVID-19 pandemic success into new innovations, but it is not currently without risk given its high multiple compared to sales figures.
The core question for investors remains whether the market has already priced in future growth or if there is hidden value awaiting realization. The divergence between the current trading price of approximately US$45.37 and higher fair value estimates depends entirely on the execution of its drug and treatment investments moving from development to commercialization. If forecasts are delayed or trial outcomes are unfavorable, the high multiple could contract quickly. While Moderna maintains a commanding fundamental position with numerous products nearing commercialization, the valuation analysis suggests that while long-term potential exists, current ratios invite caution regarding how much resilience the premium can withstand if the growth story takes longer than anticipated to play out.
📈 Q1 2026 revenue surged to $389M, up from $108M last year.
⚠️ Net loss widened to $1.34B due to substantial litigation costs.
💰 Stock trades at $45.37 vs a $175 fair value estimate by analysts.
🧬 Strong pipeline near commercialization requires minimal additional capital investment now.
⚠️ High valuation remains fragile with limited room for trial setbacks.
📈 Moderna reported Q1 2026 revenue of $389 million, representing a significant year-over-year increase from $108 million.
⚠️ The company recorded a wider net loss of $1.343 billion in the quarter, primarily driven by substantial litigation costs.
📉 Stock prices declined over the past month and year, dropping 10.57% in seven days and falling 47.02% year-to-date despite some long-term resilience.
💰 The current stock price of approximately $45.37 is trading well below a "fair value" estimate of $175 suggested by Woodworth Fund analysts.
📉 The valuation gap between the market price and the $175 fair value reflects a belief that the stock may be underpriced relative to its assets.
💡 Moderna reinvested past pandemic profits into new innovations while maintaining a strong balance sheet with relatively low debt levels.
⚖️ Current trading valuations show a Price-to-Sales ratio of 9.3x, which is significantly higher than the estimated fair ratio of 1x and the peer average of 5.4x.
🧬 The company maintains a large pipeline of drug and treatment investments that are close to commercialization without needing additional capital investment.
⚠️ Achieving the high fair value depends heavily on successful commercialization of the pipeline and avoiding significant trial setbacks or extended losses.
🔍 Analysts suggest that the stock's premium valuation is fragile and leaves limited room for error if forecasts take longer than expected to materialize.
🏦 The article notes that government research funding has been defunded, though Moderna remains in a commanding fundamental position despite this shift.
📊 Total shareholder return metrics show mixed signals, with a positive 64% one-year return contrasting with declines over three and five-year periods.
💻 This analysis is provided by Simply Wall St as general commentary based on historical data and does not constitute financial advice to buy or sell the stock.
Bullish Signals
- Moderna reported Q1 2026 revenue of US$389 million, a significant increase compared to US$108 million a year earlier.
- The company reinvested its historic pandemic windfall into new innovations while maintaining a pristine balance sheet with relatively low debt.
- Moderna trades below its book value, indicating potential for significant upside as product investments move closer to commercialization.
- Analysts' fair value analysis suggests a target price of US$175, which is nearly four times the current trading level of US$45.37.
- Despite recent litigation costs, the company retains a commanding fundamental position with numerous drug and treatment products in its pipeline.
Risk Factors
- Moderna reported a wider net loss of US$1.343 billion in Q1 2026 driven by litigation costs, signaling significant financial pressure despite revenue growth.
- The stock has suffered substantial recent declines, dropping 10.57% over the past 7 days and 47.02% year to date, indicating persistent market weakness.
- Total shareholder returns have declined over a three-year period by 66.89% and by 72.19% over five years, reflecting poor long-term investor performance.
- Analysts' average price target sits under the current level of US$45.37, with some estimates suggesting the fair value is lower than the $175 valuation used in bullish narratives.
- The company faces a potential shortfall of US$2.822b if setbacks occur in clinical trials or if heavy losses continue as predicted in some forecasts.
- Moderna trades on a P/S ratio of 9.3x, significantly higher than the estimated fair ratio of 1x and peer average of 5.4x, leaving limited room for error in valuation assumptions.
- The high premium valuation relies heavily on successful commercialization of the pipeline; any delays or failures could lead to a sharp correction as the stock trades below its book value.
Moderna Inc (MRNA) reported Q1 2026 revenue of $400 million, representing a significant $300 million year-over-year increase, with costs of sales rising to $955 million primarily due to an $878 million litigation settlement related to Arbutus and Genevant. On a GAAP basis, the company recorded a net loss of $1.3 billion for the quarter, though excluding the litigation payment, the loss stood at $0.5 billion. The company maintained a robust cash position with $7.5 billion in cash and investments as of the end of Q1 2026. Despite these financial results, revenue guidance indicates potential deceleration, with expectations for up to 10% growth in 2026 overall but a second-quarter forecast between $50 million and $100 million.
Geographically, Moderna's revenue mix showed a strong international presence at 80%, compared to 20% from the United States during the quarter. A major milestone was the approval of mCOMBRIAX, the first flu plus COVID combo vaccine, in the European Union, alongside maintained availability of Spikevax which is expected to drive EU market growth in 2027. Strategic advancements were highlighted in oncology, where Moderna initiated a Phase 3 clinical trial for intismeran in non-small cell lung cancer with a focus on early-stage disease. The company also noted the strategy of pursuing intismeran both as a monotherapy and in combination with KEYTRUDA to achieve potential cures in high-risk Stage 1 small cell lung cancer by intervening early to prevent relapse.
On the legal front, Moderna disclosed a pending litigation settlement of $950 million due in Q3 2026 but also faces potential additional liability up to $1.3 billion regarding a 1498 matter if the appeal is unsuccessful. Management, including President Stephen Hoge and CFO James Mock, expressed confidence in avoiding charges on the latter case, anticipating resolution in late 2027 or 2028. Operational updates included plans for a second UK delivery campaign for spring boosters in the fall, with interim analysis expected for the adjuvant melanoma Phase 3 trial in 2026 based on event accrual. The company acknowledged the potential for future declines in COVID vaccination rates that could impact revenue growth. GuruFocus has flagged four warning signs for MRNA, noting the challenges associated with high cash burn against strategic investment and legal contingencies.
📈 Q1 revenue hit $400M (up 300% YoY), with UK deliveries fueling growth for spring, fall, and winter campaigns.
💰 Adjusted net loss was $500M after excluding a major $878M one-time litigation settlement cost.
💉 Regulators approved mCOMBRIAX in the EU, marking the first flu plus COVID combo vaccine milestone.
🔬 Oncology pipeline advanced with Phase 3 intismeran trials starting in lung cancer and melanoma.
⚠️ International markets drove 80% of revenue, though analysts warn of future declines from dropping vaccination rates.
📈 Moderna reported Q1 2026 revenue of $400 million, representing a $300 million year-over-year increase driven by strategic partnerships like those with the UK government.
💰 The company posted a net loss of $1.3 billion on a GAAP basis, while excluding a one-time litigation settlement, the adjusted loss was $0.5 billion.
💵 Moderna holds a strong balance sheet with $7.5 billion in cash and investments at the end of Q1 2026.
📉 R&D expenses decreased by 24% year-over-year to $649 million, while SG&A expenses fell 18% to $173 million.
⚖️ A significant portion of costs was driven by a litigation settlement with Arbutus and Genevant totaling $878 million included in the cost of sales.
📅 The full $950 million litigation settlement payment is scheduled for due in Q3 2026.
🌍 Approximately 80% of revenue comes from international markets, with the remaining 20% from the United States.
⚠️ Management issued guidance expecting up to 10% revenue growth for the full year 2026 but noted a potential slowdown in Q2 projections.
💉 Moderna achieved a regulatory milestone with the EU approval of mCOMBRIAX, the first flu plus COVID combo vaccine.
🦠 Spikevax also received approval in the European Union, expected to drive growth in that market starting in 2027.
🏥 The company advanced its oncology pipeline by initiating a Phase 3 clinical trial for intismeran in non-small cell lung cancer with a focus on early-stage disease.
💬 Management clarified that the first quarter's UK delivery was for the spring campaign, with an additional fall campaign planned for Q3 and Q4.
🔬 An interim analysis for the Phase 3 trial of intismeran in adjuvant melanoma is expected to be conducted in 2026 based on event accrual.
⚖️ The CFO stated that a potential additional liability of $1.3 billion related to the 1498 case is not recorded as probable, with resolution possibly occurring in late 2027 or 2028.
📉 Analysts warned of potential future declines in COVID vaccination rates which could negatively impact revenue growth going forward.
Bullish Signals
- Revenue grew $300 million year-over-year to $400 million in Q1 2026, demonstrating strong commercial traction.
- R&D expenses decreased by 24% and SG&A expenses dropped 18%, indicating improved operational efficiency despite the net loss.
- Moderna maintains a robust cash position with $7.5 billion in cash and investments, providing ample liquidity for growth initiatives.
- The company achieved a strategic milestone with mCOMBRIAX approval in the European Union, opening new market opportunities.
- Revenue guidance anticipates up to 10% growth for 2026, signaling continued expansion beyond the current quarter.
- Moderna secured approvals for Spikevax in the European Union, driving expected growth in the EU market for 2027.
- The Phase 3 clinical trial for intismeran in non-small cell lung cancer has officially begun, diversifying the pipeline into oncology.
- Management remains optimistic about future outcomes, noting they are "confident" regarding the litigation appeal and see no need to record a charge yet.
- A second UK delivery campaign is planned for the fall, potentially creating a double year of deliveries and boosting revenue in Q3/Q4.
- Early-stage disease focus with monotherapy safety profiles looks promising for preventing relapse, opening avenues for potential cures.
- Phase 2 studies for RCC and muscle invasive bladder cancer are fully enrolled, positioning these assets to move quickly toward registrational studies if data is favorable.
Risk Factors
- The company reported a significant net loss of $1.3 billion on a GAAP basis in Q1 2026, primarily driven by an $878 million litigation settlement.
- Moderna faces potential additional liability of up to $1.3 billion if it does not prevail in its appeal regarding the litigation settlement with Arbutus and Genevant.
- A significant portion of Cost of Sales ($955 million) is attributed to litigation settlements rather than direct product costs, potentially distorting profitability metrics.
- GuruFocus has detected 4 Warning Signs for MRNA, indicating potential undisclosed risks or financial vulnerabilities.
- Revenue guidance for Q2 2026 ranges between $50 million and $100 million, representing a substantial deceleration compared to the $400 million generated in Q1 2026.
- The company anticipates potential future declines in COVID vaccination rates, which poses a direct threat to revenue growth forecasts.
- Revenue is heavily skewed geographically, with 80% coming from international markets and only 20% from the United States, increasing exposure to foreign exchange and regulatory risks abroad.
- The resolution timeline for the $1.3 billion litigation charge could extend into late 2027 or 2028, creating prolonged uncertainty over future cash flows.
Moderna Inc. is preparing to report its first-quarter earnings ahead of a Friday market open, with investors anticipating a significant revenue decline as the company transitions away from its pandemic-era dominance. Analysts project a loss of $2.02 per share on expected revenue of $251.76 million, marking a 63% drop from the $678 million reported in the fourth quarter and reflecting a slight improvement from last quarter's $2.11 per share loss. Despite this anticipated downturn, Wall Street sentiment has softened, with EPS estimates falling 36% over the past week while revenue estimates have slipped roughly 5%, contributing to a stock price of $45.72 that remains below its 52-week high of $59.55. Analyst consensus holds a neutral stance, rating Moderna as a hold with a median price target of $41.42, suggesting approximately 9% downside from current levels, though Barclays recently revised its target upward to $48 from $25.
Investors are closely evaluating whether Moderna's diverse vaccine pipeline can offset the anticipated slump in COVID vaccine sales, which will be tested through upcoming revenue guidance. The company has secured strong market penetration with its mRESVIA RSV vaccine, capturing about 34% market share in the 65-and-older demographic, while also gaining regulatory momentum with the European Commission's approval on April 21 of mCOMBRIAX, the first mRNA combination vaccine for influenza and COVID-19. Furthermore, updates on the collaboration with Merck regarding its melanoma cancer vaccine are critical; January data showed a 49% reduction in death rates over five years, keeping Phase 3 readouts as potential catalysts for growth and validating the company's strategic pivot toward non-COVID franchises.
Beyond product approvals, Moderna faces significant financial headwinds and operational challenges that could impact its path to profitability. The firm is proceeding with high-risk bird flu vaccine trials, enrolling roughly 4,000 participants in a late-stage study despite losing hundreds of millions in federal funding amid political scrutiny of mRNA technology. This quarter marks the last period before Moderna aims to execute its long-term goals of achieving up to 10% revenue growth by 2026 and reaching cash breakeven by 2028. The market will scrutinize management's ability to articulate a credible strategy for scaling from the current $251 million quarterly run rate to sustainable profitability, as this transition determines if the stock can break out of its recent trading range between $22.28 and $59.55.
📉 Moderna Q1 earnings due Friday with revenue dropping 63% sequentially to $251M.
💸 Analysts expect a $2.02 EPS loss as Wall Street sentiment turns cautious.
⚠ Stock trades near sell targets while investors await pipeline catalysts and vaccine momentum.
📉 Moderna is set to report Q1 earnings Friday morning after a 63% sequential revenue decline from $678M in Q4.
💸 Analysts forecast a Q1 loss of $2.02 per share on projected revenue of $251.76 million.
📊 Wall Street caution is evident as EPS estimates dropped 36% and revenue estimates fell roughly 5% over the past week.
🏦 The stock trades at $45.72, trading near analyst consensus targets with a majority of ratings holding or recommending sell.
💉 Investors are focused on mRESVIA RSV vaccine momentum, which currently holds 34% market share in the 65+ demographic.
💊 The European Commission's approval of mCOMBRIAX for influenza and COVID-19 represents a key growth driver for the diversified pipeline.
🔬 Melanoma cancer vaccine data showing a 49% reduction in death rates is closely watched as potential Phase 3 catalysts emerge.
🐦 Moderna continues its bird flu vaccine trial with 4,000 participants despite significant loss of federal funding and political headwinds.
🚀 The company aims for up to 10% revenue growth in 2026 and cash breakeven by 2028 following Q1 2025 reporting.
📈 Management faces the challenge of articulating a credible path from $251M quarterly revenue to sustainable profitability.
Bullish Signals
- Moderna's mRESVIA captured 34% market share in 65+ segment.
- European Commission approved mCOMBRIAX on April 21 as world's first mRNA combo vaccine for flu and COVID-19.
- Melanoma vaccine with Merck showed 49% death rate reduction over five years.
- Bird flu trial enrolling 4,000 participants in late-stage study.
- Barclays raised Moderna price target to $48 from $25 earlier this month.
- Company aims for up to 10% revenue growth in 2026 and cash breakeven by 2028.
Risk Factors
- Revenue drop ~63% amid business model pivot.
- Analysts project Q1 loss of $2.02 per share.
- EPS estimates fell 36% in past week.
- Stock trades at $45.72, 9% above target.
- Only 3 of 23 analysts rate stock buy.
- RSV vaccine momentum lacking despite 34% segment share.
- Bird flu trial proceeds despite funding losses.
- Cash breakeven goal by 2028 faces hurdles.
Bullish Signals
- Moderna's mRESVIA RSV vaccine has captured roughly 34% market share in the 65-and-older segment.
- The European Commission approved mCOMBRIAX on April 21, marking it as the world's first mRNA combination vaccine for influenza and COVID-19.
- Moderna's melanoma cancer vaccine developed with Merck showed a 49% reduction in death rates over five years in data released in January.
- Moderna continues to push ahead with its bird flu vaccine trial, enrolling roughly 4,000 participants in a late-stage study.
- Barclays raised its price target for Moderna to $48 from $25 earlier this month.
- The company aims to achieve up to 10% revenue growth in 2026 and reach cash breakeven by 2028.
Risk Factors
- Moderna is facing a sharp sequential revenue drop of approximately 63% as it pivots from its pandemic-era business model to a diversified vaccine franchise.
- Analysts expect a loss of $2.02 per share on revenue of $251.76 million for the first quarter, indicating continued profitability challenges.
- Wall Street has grown more cautious with EPS estimates falling 36% over the past week while revenue estimates have declined roughly 5% in the same period.
- The stock trades at $45.72, implying a downside risk against analyst consensus price targets of $41.42 which suggest roughly 9% downside from current levels.
- Of the 23 analysts covering the stock, only three rate it a buy while three recommend selling, reflecting significant investor skepticism.
- Investors are concerned about whether declining COVID vaccine sales can be offset by mRESVIA RSV vaccine which has captured roughly 34% market share in the 65-and-older segment but lacks broader momentum.
- Moderna is pushing ahead with its bird flu vaccine trial despite losing hundreds of millions in federal funding and facing political headwinds around mRNA technology.
- The company faces a significant challenge transitioning from a $251 million quarterly revenue run rate to sustainable profitability to achieve its stated goal of reaching cash breakeven by 2028.
The pharmaceutical industry is undergoing a strategic shift from competing on individual assets to building scalable RNA platforms that integrate biology, data science, manufacturing, and clinical development into an adaptive engine. This transition moves competition away from molecule-by-molecule dynamics toward systems that generate therapies efficiently. While RNA began as a pandemic-driven validation, it has evolved into a programmable approach where success depends on creating fast design–test–learn loops that compound into structural advantages over time. Companies must now ask not just if a molecule works, but how quickly they can learn across many molecules and translate those insights into better outcomes.
Moderna is extending its platform beyond infectious diseases into oncology, rare diseases, and personalized medicine, relying on years of accumulated learning in mRNA design, delivery, and manufacturing to maintain its lead. While early signals in cancer vaccines are promising, the core strategic question remains whether this capability can translate into sustained, diversified value or if Moderna will be viewed as a pandemic-era outlier. Pfizer, having gained significant scale through its 2018 partnership with BioNTech which produced one of the first approved mRNA vaccines, now faces a more complex choice due to revenue normalization, pipeline pressure, and looming patent cliffs. As RNA expands, Pfizer must decide whether to continue leveraging partnerships for flexibility or build deeper internal capabilities, potentially even acquiring assets to gain full control over the platform rather than merely partnering on it.
Bristol Myers Squibb is approaching RNA differently by using acquisition as a primary method to reshape its future portfolio amid the expected loss of exclusivity for its flagship immunotherapy Opdivo (nivolumab) toward the end of the decade. To accelerate this transition, BMS recently executed a $1.5 billion acquisition of Orbital Therapeutics, gaining access to proprietary RNA technologies combining circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design for applications in autoimmune disease, oncology, and next-generation vaccines. The critical challenge for all three companies lies in execution; integrating these advanced capabilities across research, manufacturing, and clinical development requires time to generate meaningful outputs, and BMS is specifically working to compress that timeline. Ultimately, the market will judge winners by who builds the most effective platforms to repeatedly produce high-value therapies within their respective strategic contexts.
📉 Pharma competition now focuses on scalable platforms integrating biology, data, and manufacturing for system-based innovation.
💊 Pfizer faces patent cliffs but must choose between partnerships or building full RNA platform control through acquisition.
🧬 BMS acquired Orbital Therapeutics for $1.5B to access circular/linear RNA capabilities while avoiding organic development risks.
⚠ All three firms face execution challenges in integrating research, manufacturing, and clinical development into adaptive engines.
🏆 Winners will be those transforming organizations into true platform-native biopharma entities with continuous learning systems.
📉 Pharma competition is shifting from individual assets to scalable platforms that integrate biology, data science, and manufacturing.
💉 RNA serves as a programmable approach to drug development that accelerates the transition to system-based innovation.
🏆 The core strategic tension now centers on who builds the fastest design–test–learn loops to create structural advantages.
🔬 Moderna is extending its post-COVID identity beyond infectious diseases into oncology, rare diseases, and personalized medicine.
📈 Early signals in Moderna's individualized cancer vaccines are promising, but sustained value depends on translating accumulated learning into diversified revenue.
💊 Pfizer leveraged its BioNTech partnership to dominate the mRNA market during COVID, but now faces patent cliffs and internal capability gaps.
🤝 Pfizer must decide whether to maintain flexibility via partnerships or build full control over RNA platforms through acquisition or integration.
🧬 Bristol Myers Squibb (BMS) is entering the RNA space through acquisition rather than organic development to counter revenue decay from Opdivo's impending patent loss.
💰 BMS acquired Orbital Therapeutics for $1.5 billion to gain access to circular/linear RNA engineering, lipid nanoparticle delivery, and AI-driven design capabilities.
🎯 This deal allows BMS to apply its new RNA platform across autoimmune disease, oncology, and next-generation vaccines without building capability from scratch.
⚠️ All three companies face execution challenges in integrating research, manufacturing, and clinical development into a single adaptive engine.
🔄 The industry standard is now shifting toward companies that can repeatedly produce high-value therapies through continuous learning systems.
🏆 The winners will be those who transform their organization from program-optimizers to true platform-native biopharma entities.
📅 Key timelines and patent cliffs for Opdivo are pressuring BMS to accelerate its RNA portfolio growth within the next decade.
🔍 Executive leadership across all three firms is being evaluated on how effectively they evolve their strategic posture beyond their pandemic-era success.
Bullish Signals
- Bristol Myers Squibb acquired Orbital Therapeutics for $1.5 billion to gain RNA platform capabilities.
- The deal adds early-stage therapies in autoimmune disease, oncology, and vaccines to BMS's pipeline.
- Moderna's years of mRNA innovation created a competitive head start for competitors to match.
- Moderna's cancer vaccine signals show promise beyond infectious diseases into oncology and rare diseases.
- Pfizer established a top industry partnership strategy through its collaboration with BioNTech.
- The Pfizer-BioNTech alliance set benchmarks for speed, scale, and global reach in COVID-19 vaccines.
- RNA technology rewards integration of biology, data science, and clinical development into adaptive engines.
- Industry is shifting to scalable platforms with structural advantages for fastest design-test-learn loops.
Risk Factors
- Moderna must prove platform scalability beyond infectious diseases.
- Early cancer vaccine signals remain undefined for Moderna.
- Failure risks Moderna as pandemic outlier versus durable biopharma model.
- Pfizer benefits from RNA without ownership under revenue normalization.
- Patent cliff and post-COVID environment challenge Pfizer growth trajectory.
- Pfizer must choose partnerships or build deeper internal capabilities.
- BMS needs new growth drivers as Opdivo loses exclusivity near decade end.
- The $1.5 billion BMS acquisition carries execution risks for RNA integration.
- BMS accelerated timeline approach may not justify investment quickly.
Bullish Signals
- Bristol Myers Squibb completed a $1.5 billion acquisition of Orbital Therapeutics to access a proprietary RNA platform combining circular and linear RNA engineering, lipid nanoparticle delivery, and AI-driven design.
- This acquisition provides BMS with early-stage RNA therapies in autoimmune disease, oncology, and next-generation vaccines, enabling it to reshape its future portfolio as key assets mature.
- Moderna has accumulated significant years of iteration in mRNA design, delivery, and manufacturing, giving it a head start that is difficult for competitors to replicate quickly.
- Moderna's early signals in individualized cancer vaccines are showing promise, suggesting the platform can scale beyond infectious disease into oncology and rare diseases.
- Pfizer established one of the most successful partnership strategies in industry history through its collaboration with BioNTech, producing one of the first approved mRNA vaccines.
- The Pfizer-BioNTech alliance set a new benchmark for speed, scale, and global reach during the development of COVID-19 vaccines, demonstrating proven execution capabilities.
- RNA technology represents a programmable approach to drug development that rewards companies for integrating biology, data science, manufacturing, and clinical development into a single adaptive engine.
- The industry is shifting towards scalable platforms rather than competing solely on individual assets, creating structural advantages for those who build the fastest design–test–learn loops.
Risk Factors
- Moderna faces pressure to demonstrate its platform can successfully scale beyond infectious diseases into oncology and rare diseases, with early cancer vaccine signals not yet definitive.
- If Moderna fails to translate its accumulated capability into sustained value, it risks being viewed as a pandemic-era outlier rather than a durable biopharma model.
- Pfizer faces a complex strategic position as it benefited from the RNA platform without fully owning it, forcing a reassessment under revenue normalization and pipeline pressure.
- A looming patent cliff and post-COVID environment are challenging Pfizer's growth trajectory, requiring a difficult choice between relying on partnerships or building deeper internal capabilities.
- Bristol Myers Squibb faces an urgent need to build new growth drivers as key assets like its flagship therapy Opdivo approach loss of exclusivity toward the end of the decade.
- The $1.5 billion acquisition by BMS is a significant capital outlay that comes with execution risks, as RNA platforms require time for integration and meaningful outputs.
- BMS faces a critical question on whether its accelerated approach to compressing timelines can deliver learning and value fast enough to justify the investment.
Moderna (MRNA) is set to report its first-quarter earnings on Friday, May 1, before the market opens, as investors closely monitor the company’s performance following a prolonged post-pandemic downturn. The primary focus will be on whether the company can demonstrate signs of revenue stabilization after experiencing a sharp decline in sales once the massive COVID-19 vaccine orders ended. This quarter represents a critical test for Moderna as it transitions away from its pandemic-era windfall and seeks to reestablish sustainable growth in a competitive therapeutic landscape.
Since the conclusion of the global health crisis, Moderna has struggled to maintain the revenue momentum achieved during the pandemic, with total revenues showing a significant downward trend. The market will be keen to assess not only the magnitude of this contraction but also management’s ability to pivot toward successful new therapies and partnerships that could offset declining vaccine sales. Analysts and shareholders are particularly interested in seeing if the company can achieve profitability or at least narrow its losses, which have persisted through this challenging transition period.
Beyond the headline revenue figures, investors will scrutinize key metrics such as gross margins, operating expenses, and progress on key development programs, including its oncology pipeline and infectious disease initiatives. Any positive commentary from management regarding long-term growth strategies or successful commercial launches could help alleviate concerns about the company's financial health in this new phase. Conversely, if the earnings miss expectations or reveal deeper structural challenges, it could weigh heavily on the stock as the market grapples with the reality of a post-pandemic biotech landscape that has changed significantly from the pandemic boom era.
📅 Moderna reports Q1 earnings before market open on Friday, May 1.
📉 Investors watch for revenue stabilization after the pandemic downturn.
💸 Financial performance has declined since the vaccine windfall ended.
📉 Revenue streams drop as initial demand subsides.
📅 Moderna (MRNA) is scheduled to report first-quarter earnings on Friday, May 1, before market open.
📉 Investors are closely watching for signs of revenue stabilization following a prolonged post-pandemic downturn.
💸 The company has experienced struggling financials since the end of the COVID-19 vaccine windfall era.
📉 Revenue streams have been declining as the initial pandemic-driven demand subsides.
Bullish Signals
- Moderna reports Q1 earnings Friday May 1 ahead of market open.
- Results offer opportunity to assess post-pandemic stabilization signs.
- Upcoming data signals potential revenue rebound inflection point.
Risk Factors
- Moderna revenue declined post-COVID-19 pandemic.
- Investors fear prolonged downturn amid earnings.
- Significant losses persist despite stabilization efforts.
Bullish Signals
- Moderna is set to report first-quarter earnings on Friday, May 1, ahead of market open, providing an opportunity for investors to assess signs of stabilization following the post-pandemic downturn.
- The company's upcoming results are closely watched as a key potential inflection point that could signal a revenue rebound.
Risk Factors
- Moderna continues to struggle following the end of the COVID-19 pandemic, with revenue declining from its previous peak.
- Investors are concerned about a prolonged post-pandemic downturn as the company faces an earnings report where revenue rebound is in focus.
- The company persists with significant losses despite attempts to stabilize after the windfall period.
Moderna (NASDAQ:MRNA) is scheduled to report its quarterly earnings on Friday, May 1, 2026. The company currently holds a market capitalization of $18 billion and has generated revenue of $1.9 billion over the last twelve months. Financially, Moderna remains operationally loss-making with operating losses of $-3.1 billion and net income of $-2.8 billion. Market analysis indicates that future stock performance will likely be determined by how the earnings results and forward outlook compare against prevailing investor expectations. Investors interested in event-driven trading strategies are advised to review historical post-earnings reaction data to position trades prior to the announcement or to analyze correlations between short-term and medium-term returns one day after the report is released.
Historical data suggests various approaches for trading around earnings announcements, such as leveraging correlations between one-day, five-day, and twenty-one-day returns over a five-year or three-year history. A less risky strategy noted involves identifying pairs of timeframes with the highest correlation to execute trades accordingly; for instance, if one-day and five-day returns show high correlation, traders might position long for the next five days if the immediate one-day return is positive. The analysis also highlights that while single-stock trading carries inherent risks regardless of strategy robustness, diversified solutions like the Trefis High Quality Portfolio offer a market-beating track record by aggregating insights from 30 stocks to provide better returns with less risk compared to broad benchmarks including the S&P 500 and Russell 2000 indices.
In the broader market context mentioned alongside Moderna's upcoming results, several other biotech and technology-related entities have experienced significant volatility, with examples such as ON Semiconductor stock surging 57% with a 14-day winning streak, Cummins climbing 9.2%, Lockheed Martin dropping 15%, and Amkor Technology rising 22%. Additionally, market breadth data notes that specific segments of the S&P 500, including large-cap, mid-cap, and small-cap stocks, are trading at 52-week highs, while a broader list of stocks is categorized by their position relative to their 52-week range. These market movements provide context for how investors may perceive risk and opportunity in high-profile earnings events like Moderna's upcoming disclosure.
📅 Moderna earnings scheduled for Friday, May 1, 2026.
💰 Revenue hit $1.9B last twelve months with operational losses.
⚠ Diversified portfolios recommended over single stock picking.
🏆 Trefis High Quality Portfolio beats major benchmarks consistently.
🌍 ON Semiconductor gained 57% while Lockheed Martin dropped 15%.
📅 Moderna is scheduled to report earnings on Friday, May 1, 2026.
💰 The company currently has a market capitalization of $18 billion.
📉 Recent financial data shows $1.9 billion in revenue over the last twelve months.
❗ The company reported operational losses of $3.1 billion and net income of $2.8 billion.
📊 Analysts suggest trading strategies based on historical post-earnings returns.
🔍 Traders can analyze correlations between one-day, five-day, and twenty-one-day returns.
💡 A strategy involves identifying high correlation periods to position trades for the next five days if one-day returns are positive.
⚠️ Stock picking may fail even with a good strategy without diversification.
🏆 The Trefis High Quality Portfolio offers a diversified approach using 30 stocks.
📈 The HQ Portfolio track record shows outperformance against S&P 500, mid-cap, and Russell 2000 benchmarks.
🎢 This diversified portfolio aims to reduce risk compared to individual stock volatility.
🌍 Other market movers include ON Semiconductor rising 57% and Lockheed Martin dropping 15%.
Bullish Signals
- Moderna to report earnings May 1, 2026, an upcoming investor catalyst.
- Trefis High Quality Portfolio offers upside with diversified 30-stock holdings outperforming benchmarks.
- ON Semiconductor rose 57% with a 14-day winning streak.
- Amkor Technology stock jumped 22% on a 6-day winning streak.
- Cummins Stock climbed 9.2% amid a 6-day winning spree.
Risk Factors
- Moderna operationally loss-making with $3.1B operating losses and $2.8B net income.
- Market cap of $18B far exceeds last 12 months revenue of $1.9B, suggesting high valuation.
- Stock reaction heavily depends on meeting investor expectations, creating significant trader risk.
- Stock picking can fail regardless of strategy due to inherent volatility and unpredictability.
Bullish Signals
- Moderna is set to report earnings on Friday, May 1, 2026, providing an upcoming catalyst for investors.
- The Trefis High Quality Portfolio offers a way to achieve upside with a smoother ride by diversifying across 30 stocks that collectively outperform the S&P 500, S&P mid-cap, and Russell 2000 benchmarks.
- ON Semiconductor demonstrated strong momentum with a 57% surge and a 14-day winning streak, showcasing positive market sentiment in the sector.
- Amkor Technology Stock Rockets 22% With 6-Day Winning Streak.
- Cummins Stock enjoyed a 6-Day Winning Spree, climbing 9.2%, indicating robust performance among portfolio constituents.
Risk Factors
- Moderna is operationally loss-making with significant $-3.1 Bil in operating losses and $-2.8 Bil net income, raising concerns about long-term profitability.
- The company's current market capitalization of $18 Billion significantly outweighs its last twelve months' revenue of $1.9 Billion, suggesting a high valuation relative to earnings potential.
- Historical post-earnings return data shows that Moderna stock reaction depends heavily on meeting investor expectations, creating significant risk for traders if results disappoint.
- The article emphasizes stock picking can fail regardless of strategy, highlighting the inherent volatility and unpredictability associated with individual stock trades like MRNA.
Moderna (MRNA), a developer of mRNA-based therapeutics and vaccines, has experienced a significant decline in its stock price over the past five trading days. The company's shares have fallen 18% cumulatively during this losing streak, resulting in an approximate $3.9 billion reduction in its market capitalization. With the stock currently valued at $18 billion, investors are evaluating whether this downturn represents a buying opportunity or a sign of underlying weakness. Analysts note that Moderna faces concerns regarding its weak operating performance and financial condition, compounded by what is described as a very high valuation, leading to a classification of the stock as unattractive for investment.
The article suggests that while the current headlines reflect market movements, individual risk management should focus on predictive signals rather than reacting after news breaks. Trefis provides historical context by highlighting that among S&P 500 constituents, there are currently 92 stocks experiencing streaks of three or more consecutive losses and 33 stocks with similar winning streaks. This data aims to help investors distinguish between temporary market dips and long-term value traps by examining past performance patterns during similar drawdown periods.
In contrast to Moderna's struggles, the High Quality Portfolio, which consists of 30 stocks, has maintained a track record of outperforming its benchmark across the S&P 500, S&P MidCap, and Russell 2000 indices. This portfolio strategy is credited with delivering better returns with lower risk through reduced volatility compared to the broader market roller-coaster effects seen in individual stocks like Moderna. Meanwhile, other notable market movements include On Semiconductor rising 57% over a 14-day period, Lockheed Martin dropping 15% over eight days, and various other companies like Cummins, Amkor Technology, and GLOBALFOUNDRIES showing significant short-term volatility ranging from surges to plunges.
📉 Moderna stock fell 18%, causing a $3.9 billion market cap drop.
⚠ Analysts recommend selling due to high valuation concerns despite recent losses.
🏆 Trefis High Quality Portfolio outperforms benchmarks with lower risk and volatility.
🔒 Using predictive signals helps mitigate stock-specific drawdowns before news headlines.
📉 Moderna stock experienced an 18% decline over a five-day period, resulting in a $3.9 billion drop in market capitalization.
💰 The current market cap of Moderna stands at approximately $18 billion following the recent losses.
⚠️ Investors cite weak operating performance and financial condition as reasons to fear the stock.
📉 Analysts recommend a sell rating due to concerns over Very High valuation despite the price drop.
📊 Historical analysis suggests managing individual stock risk requires predictive signals rather than waiting for news headlines.
📈 Comparative data shows 92 S&P constituents have endured three or more days of consecutive losses, while only 33 have had gains.
🏆 Trefis High Quality Portfolio outperforms benchmarks including the S&P 500 with lower risk and reduced volatility.
🔒 The article advocates using predictive signals to mitigate stock-specific drawdowns before market movements occur.
💸 Other recent market movers include ON Semiconductor surging 57% and Lockheed Martin plummeting 15%.
📉 Small-cap, mid-cap, and large-cap stocks are tracked for their performance relative to 52-week highs and lows.
Bullish Signals
- Moderna operates in high-growth biotech with significant upside potential.
- Stock maintains $18B market cap despite recent volatility.
Risk Factors
- Stock down 18% over last 5 trading days.
- Market cap dropped $3.9 billion to $18 billion.
- Analysts warn weak performance and poor financial condition.
- Very high valuation makes stock unattractive.
- Among 92 S&P constituents on losing streaks.
Bullish Signals
- Moderna's mRNA-based therapeutics and vaccines position it within a high-growth biotechnology sector with significant future upside potential.
- Despite recent volatility, the stock has maintained a market cap of $18 Bil, indicating continued investor interest in its technology platform.
Risk Factors
- Moderna stock has experienced a cumulative decline of -18% over the last 5 trading days, reflecting a 5-day losing streak that lacks investor confidence.
- The company's market cap has crashed by approximately $3.9 billion in this short period, now sitting at only $18 billion valuation.
- Analysts warn of Weak operating performance and a poor financial condition as significant risks for the stock's long-term prospects.
- Despite the price drop, the company retains a Very High valuation which makes it considered Very Unattractive to current investors.
- Moderna is currently among 92 S&P constituents that are on streaks of 3 or more consecutive losses, indicating broader market weakness.
Moderna Inc. (MRNA) experienced a significant decline in its stock price, recording an 18% drop over a five-day losing streak that resulted in a market capitalization reduction of approximately $3.9 billion. The company's market cap now stands at $18 billion. Trefis highlights concerns regarding Moderna's weak operating performance and financial condition, noting that the stock is currently trading at a very high valuation. Consequently, the analysis suggests the stock may be very unattractive for investment, raising questions about whether the current downturn represents a buying opportunity or a trap given the company's overall fundamentals.
The article emphasizes that investors often react to news after it breaks, but effective risk management requires predictive signals to mitigate individual stock risk before market headlines emerge. Trefis promotes its High Quality Portfolio model as a solution to manage such drawdowns better than holding individual stocks, noting that the portfolio has a track record of outperforming benchmarks including the S&P 500, S&P MidCap, and Russell 2000 indices with less risk and reduced volatility. The context provided includes comparisons to other recent market movements, such as Cummins climbing 9.2% over six days and Lockheed Martin falling 15% over eight days, illustrating the broader market environment where stocks are moving at 52-week highs or lows.
Historical data indicates that S&P 500 constituents have shown varying streaks of consecutive gains and losses, with 33 constituents currently experiencing three or more days of consecutive gains and 92 experiencing similar loss streaks. While Moderna's specific dip is under scrutiny, the broader section details various sectors including large cap, mid cap, small cap, and S&P 500 stocks trading at yearly highs and lows. The S&P 500 movers highlight current winners such as URI, TXN, and WST alongside losers like NOW, LULU, and FCX, providing a snapshot of market performance trends alongside Moderna's specific financial metrics for the last two fiscal quarters which are cited as reasons for investor lack of confidence.
📉 Moderna dropped 18% over five days, reducing market cap by $3.9B to $18B.
⚠ Selling driven by weak fundamentals and high valuation concerns relative to earnings.
🔄 Recent declines align with broader S&P losses while High Quality Portfolio outperforms.
📉 Moderna (MRNA) experienced an 18% cumulative stock decline over a 5-day period.
💸 The company's market cap dropped by approximately $3.9 billion during this losing streak.
💰 Current valuation stands at $18 billion following the significant drop in share price.
⚠️ Investors cite weak operating performance and financial condition as reasons for selling pressure.
📊 High valuation relative to fundamentals makes the stock appear unattractive to analysts.
📈 Historical dip analysis is recommended to determine if previous downturns were buying opportunities.
🔍 Market participants note that negative headlines have already been priced into the stock price.
🛡️ Predictive risk models are suggested for managing stock-specific drawdowns before news hits.
🏆 The High Quality (HQ) Portfolio track record shows outperformance with less volatility than the benchmark.
📊 There are currently 92 S&P constituents with 3 or more consecutive days of losses.
🔄 Several other S&P 500 stocks like Lockheed Martin and Cummins recently saw significant price swings.
🏢 Large, mid, small, and large cap stocks across the market are mixed in their 52-week trading positions.
📉 The losing streak for MRNA contrasts with the performance of the High Quality Portfolio group.
Risk Factors
- Stock lost 18% in 5 days.
- Market cap crashed $3.9B in 5 days.
- Analysts cite weak performance and deterioration.
- Valuation appears too high vs fundamentals.
Risk Factors
- Moderna (MRNA) stock hit a 5-day losing streak with cumulative losses amounting to -18%, indicating sustained downward pressure.
- The company's market cap has crashed by about $3.9 billion over the last 5 days, with current valuation standing at only $18 billion.
- Analysts highlight Moderna's overall weak operating performance and deteriorating financial condition as primary concerns for investors.
- The stock is described as having a very high valuation relative to its fundamentals, making it deemed very unattractive by the analysts.
Moderna Inc. stock recently entered its fifth consecutive day of losses, resulting in an 18% cumulative decline over the five-day period as of the article's publication on April 30, 2026. During this streak, the company's market capitalization dropped by approximately $3.9 billion, reducing its valuation to $18 billion. The decline highlights significant investor concern regarding Moderna's weak operating performance and financial condition. Analysts from Trefis caution that while these metrics present risks, the stock is also considered very unattractive due to its historically high valuation, which exacerbates the negative sentiment in the current market environment.
The article contextualizes this individual stock performance by noting that the market has already priced in the recent news, suggesting that investors seeking risk mitigation should rely on predictive signals rather than reacting to post-event headlines. It provides a broader market perspective by highlighting that among S&P 500 constituents, there are currently 92 stocks experiencing at least three consecutive days of losses compared to only 33 with similar streaks of gains. This data underscores the extent of the short-term downturn Moderna is facing within the wider index.
In contrast to the volatility seen in single-name performance, Trefis promotes its High Quality Portfolio, which consists of 30 selected stocks, as a strategy for managing risk and reducing drawdowns. The firm asserts that this collection has historically outperformed the S&P 500, S&P mid-cap, and Russell 2000 benchmarks by delivering better returns with less volatility over various periods. The piece concludes with standard disclaimers regarding data delays from NASDAQ and NYSE, noting a 15- to 20-minute lag for certain market feeds, and references financial consensus estimates provided by QuoteMedia.
📉 Moderna stock fell 18% over five days as market cap dropped $3.9B.
⚠ Analysts cite weak performance and high valuation making it unattractive.
🔍 S&P constituents face similar loss streaks despite news already priced in.
💰 High quality portfolios outperform benchmarks with less risk and volatility.
📉 Moderna (MRNA) stock experienced its fifth consecutive day of losses, with cumulative shares dropping approximately 18% over the period.
💸 The company's market capitalization fell by around $3.9 billion during the same timeframe to reach $18 billion.
⚠️ Analysts characterize Moderna as unattractive due to weak operating performance and a combination of poor financial condition with high valuation.
📊 Market sentiment suggests that this specific downturn has already been priced in by investors prior to recent headlines.
🔍 Trefis notes that 92 S&P constituents are currently experiencing streaks of three or more consecutive days of losses.
💰 In contrast, Trefis' High Quality Portfolio is outperforming benchmark indices like the S&P 500 with less risk and volatility.
🤖 The article suggests using predictive risk models to manage individual stock drawdowns rather than reacting to news notifications.
Bullish Signals
- Moderna stock trades at $18B market cap after declining.
- High Quality Portfolio outperformed major S&P and Russell benchmarks.
- Market priced in recent Moderna news, hinting at upside.
Risk Factors
- Stock fell 18% over five days with a $3.9 billion market cap loss.
- Weak performance and high valuation make shares very unattractive.
- No positive news counters recent declines or ongoing uncertainty.
Bullish Signals
- Moderna stock currently trades at a market capitalization of $18 billion, suggesting the price has already adjusted significantly following recent declines.
- High Quality Portfolio demonstrates a track record of comfortably outperforming its benchmark across S&P 500, S&P mid-cap, and Russell 2000 indices, providing a model investors can consider for managing stock-specific drawdowns.
- The article indicates that the market has already priced in recent negative news regarding Moderna, implying potential stabilization or further upside if fundamentals improve.
Risk Factors
- Moderna (MRNA) stock hit a 5-day losing streak with cumulative losses amounting to -18% and the company market cap has crashed by about $3.9 billion over this period.
- The article highlights fears regarding Moderna's weak operating performance and financial condition, making the stock Very Unattractive given its very high valuation.
- There are no positive news to counterbalance the recent -18% move, suggesting the market has already priced in negative developments but investors remain exposed to ongoing uncertainty.
Biotechnology company Moderna (NASDAQ: MRNA) is preparing to report earnings this Friday morning, with market expectations for a significant shift from last year's performance. Analysts anticipate Moderna’s revenue will grow 131% year on year, marking a reversal from the 35.3% decrease recorded in the same quarter last year. However, recent analyst sentiment has turned increasingly bearish, as revenue estimates have seen majority downward revisions over the past 30 days. Notably, Moderna previously beat analysts’ revenue expectations by reporting $678 million, which represented a 29.8% decline year on year, yet it still exceeded EPS and revenue estimates at that time.
Comparative performance among peers provides some context as Biogen delivered a 1.9% year-on-year revenue growth and AbbVie reported revenues up 4.8%, though both had varying impacts relative to their respective estimates with Biogen beating expectations by 11.2% and AbbVie falling short by 5.2%. The broader biotechnology sector has shown positive momentum, with share prices rising an average of 6.4% over the last month, while Moderna has declined 10.4% during the same period. Heading into earnings, the company currently trades at a price of $45.54 against an average analyst price target of $41.42, reflecting current market skepticism despite its historical track record of rarely missing Wall Street revenue estimates.
Investors are watching closely as this upcoming report could define the trajectory for Moderna’s stock and position relative to competitors like Biogen and AbbVie who have recently released their Q1 results. The expectation for a 131% revenue increase is substantial, yet the recent downward revisions in analyst estimates suggest caution may prevail in how the market interprets these figures upon release. With biotech investors showing resilience in the sector generally, Moderna’s performance could either solidify its standing as a resilient player or highlight ongoing challenges that have not yet fully impacted its bottom line.
📅 Moderna reports earnings this Friday morning after last quarter beat revenue despite decline.
🎯 Analysts expect 131% YoY revenue growth this quarter, reversing previous downward trend.
⚠ Sentiment is bearish with recent price target ($41.42) below current stock price ($45.54).
📅 Moderna is scheduled to report quarterly earnings results this Friday morning.
💰 Last quarter, the company beat revenue expectations with $678 million reported despite a 29.8% year-on-year decrease.
🎯 This quarter, analysts expect revenue to grow significantly by 131% year on year, reversing last year's decline.
⚠️ Analyst sentiment is increasingly bearish with downward revenue revisions over the past 30 days.
🤝 Peers like Biogen and AbbVie reported their Q1 results recently, providing some market context for comparisons.
📉 Investors have shown mixed sentiment in the biotech sector, with Moderna down 10.4% this month while peers gained 6.4%.
💵 The average analyst price target is $41.42, which is below the current stock price of $45.54.
📜 The company has a history of rarely missing Wall Street's revenue estimates historically.
Bullish Signals
- Moderna beat analysts' revenue with $678 million and strong EPS.
- Revenue grew 131% YoY, reversing last year's 35.3% decline.
- Rarely misses Wall Street estimates, showing consistent operational strength.
Risk Factors
- Revenue dropped 29.8% year on year.
- Analysts revised revenue estimates down over 30 days.
- Stock down 10.4% month amid biotech gains of 6.4%.
- Price $45.54 above target $41.42 risks downside.
- Revenue expected to rise 131% may not materialize.
Bullish Signals
- Moderna beat analysts' revenue expectations last quarter, reporting revenues of $678 million with a beat of analysts' EPS and revenue estimates.
- Market expectations for this quarter show Moderna's revenue growing 131% year on year, representing a significant reversal from the 35.3% decrease recorded in the same quarter last year.
- Moderna rarely misses Wall Street's revenue estimates, indicating consistent operational strength despite broader market headwinds.
Risk Factors
- Moderna's revenue dropped 29.8% year on year, despite beating estimates last quarter.
- Analysts have grown increasingly bearish with majority downward revisions to revenue estimates over the last 30 days.
- The stock is down 10.4% over the last month compared to the broader biotechnology segment which rose 6.4%.
- Current share price of $45.54 trades above the average analyst price target of $41.42, suggesting potential downside if earnings are missed.
- Last quarter's revenue growth was 35.3% decline, with market now expecting a strong 131% reversal which may not materialize given peer performance like Biogen beating expectations by only 11.2% or AbbVie missing estimates by 5.2%.
The provided text titled "Moderna Earnings Notes" from Insight Guru Inc., dated 4/29/2026, serves as a landing page for financial data rather than containing specific earnings report details or analysis of Moderna's (MRNA) business performance. The content focuses on providing access to historical market reactions and earnings result history for the biotechnology company, noting that it displays a consolidated view of how MRNA has performed in past earnings releases.
Specific financial metrics such as Operating Income Growth, Net Income Growth, and EPS Growth are highlighted in the text as having missing data; this is attributed to a negative base figure from the previous period, which renders growth calculations meaningless for those specific line items. Consequently, the page explicitly states that growth figures are not calculated for these categories in instances where the denominator is negative.
The document also includes standard financial data disclaimers regarding its operation and source. It specifies that consensus EPS estimates are sourced from QuoteMedia and are updated on a weekly basis (every weekday). Market data displayed through the interactive model, specifically NYSE/AMEX data, is noted as being delayed by 20 minutes, while NASDAQ and other data have a delay of 15 minutes unless otherwise indicated. Additionally, the text warns users about functional limitations within its interactive modeling tool, such as limits on the number of drivers that can be modified in a single scenario and minimum or maximum value constraints for certain current drivers.
The final paragraph outlines user agreement terms and rights ownership related to the website's usage. By accessing the site, users agree to be bound by Insight Guru Inc.'s Terms of Use, and all content is copyrighted as of 2026. The financial data powering the platform is attributed to Quotemedia.com, and the text reiterates that all rights remain reserved with Insight Guru Inc.
📅 Page updated 4/29/2026 for Moderna's 2025 Q4 earnings results.
❌ Growth metrics excluded due to negative financial bases.
⚠ Market data delayed 15-20 minutes across major exchanges.
📅 The page was last updated on 4/29/2026 regarding Moderna's 2025 Q4 earnings results.
📉 Growth figures for Operating Income, Net Income, and EPS are not calculated due to negative bases that make the numbers meaningless.
💼 Earnings reaction data is displayed through market history and interactive models powered by Quotemedia.com.
⚠️ Financial market data shown on the site is delayed by 20 minutes for NYSE/AMEX and 15 minutes for NASDAQ.
🤖 The interactive model includes specific limits on modifying drivers within a single scenario.
🔒 Some scenario drivers cannot be modified because they are linked to parent scenarios that have already changed them.
⚖️ Users agree to the Terms of Use upon accessing the site, which is owned by Insight Guru Inc.
Bullish Signals
- Moderna reported Q4 2025 earnings showing continued investor interest.
- Despite missing metrics, stock trades on NYSE/AMEX with real-time data.
Risk Factors
- Article contains no actual earnings data or fundamentals.
- Operating income and EPS growth metrics are missing.
- Data delays up to 20 minutes may impact trading decisions.
- Driver limits restrict scenario analysis flexibility.
- Some driver values have minimum or maximum limits.
- Scenario drivers linked to parent scenarios cannot be changed.
- Earnings history lacks specific numerical performance metrics.
- Website access requires Terms of Use agreement.
- Market reaction history section provides no stock insights.
- Data may be future-dated rather than historical actuals.
Bullish Signals
- Moderna (MRNA) recently reported Q4 2025 earnings results, indicating continued market activity and investor interest in the company.
- Despite some financial metrics being unavailable due to negative base effects, Moderna maintains a presence on major exchanges including NYSE/AMEX with available real-time data feeds for tracking performance.
Risk Factors
- The article contains no actual earnings data or fundamental business information about Moderna, consisting only of website interface text and disclaimers.
- Operating Income Growth, Net Income Growth, and EPS Growth results are missing due to negative bases, making these key metrics meaningless for analysis.
- Data delays up to 20 minutes (NYSE/AMEX) and 15 minutes (NASDAQ) could impact real-time trading decisions based on reported earnings.
- The interactive model has a limit on the number of drivers that can be modified in a single scenario, limiting scenario analysis flexibility.
- Some driver values have minimum or maximum limits which may restrict custom financial modeling for analysts.
- Scenario data is linked to a parent scenario where certain drivers are already modified and cannot be changed within the current view.
- The earnings result history lacks specific numerical performance metrics as it only references historical observation without providing the actual consolidated view data.
- Website usage requires agreement to Terms of Use, indicating potential legal compliance obligations for accessing financial market data.
- Market reaction history section provides no specific content, offering no insight into stock price movements or investor sentiment surrounding recent earnings releases.
- The copyright notice indicates the content is from Insight Guru Inc. dated 4/29/2026, which may represent future-dated or simulated data rather than historical actuals.
Moderna is scheduled to report its first-quarter 2026 earnings results on May 1, shortly before the opening bell. The Zacks Consensus Estimate projects product sales of $223.5 million and an earnings loss of $2.29 per share, with both metrics indicating improvement compared to the prior-year period. In the previous quarter, Moderna beat estimates by 18.85%, a performance that is part of a broader trend where the company has beaten analyst expectations in each of the trailing four quarters, delivering an average surprise of 34.40%. However, analysts do not predict another earnings beat for this reporting period based on current data models.
Revenue drivers are expected to come primarily from sales of Moderna's two COVID-19 vaccines, Spikevax and mNexspike, with significant anticipated sales from the RSV vaccine, mResvia. Despite these core products, expectations for mResvia remain modest due to stiff competition and strong market footholds held by RSV vaccines from GSK and Pfizer. Investors are also anticipated to seek updates on the commercialization plans for mCombriax, a combination vaccine against COVID-19 and influenza that received approval in the EU earlier this month. This marks Moderna's fourth marketed product; the initial filing for mCombriax was previously withdrawn after the agency requested additional efficacy data, an issue that was subsequently resolved with positive late-stage data announced in June 2025 regarding its flu component.
The article highlights the company's diverse development pipeline, which includes more than 30 mRNA-based investigational candidates across various stages of clinical studies, targeting indications such as cancer. A key focus for investors will be autogene, a personalized cancer therapy developed in collaboration with Merck, which is currently being evaluated in three pivotal phase III studies for melanoma and non-small cell lung cancer, with additional mid-stage studies planned for bladder and renal cancers. Year to date, Moderna shares have rallied 65% against the industry's 1% decline. While the company carries a Zacks Rank of #3 and has an Earnings ESP of -25.75%, indicating lower odds for beating estimates compared to other highlighted biotech stocks like Agenus or Inovio, its historical performance remains a significant factor in investor analysis ahead of the earnings release.
📅 Moderna reports Q2 earnings on May 1, with analysts expecting sales up but EPS losses shrinking from prior year.
💊 Revenue focused on COVID vaccines while EU approved new mCombriax flu/COVID combination therapy for launch later in year.
🔬 Pipeline includes 30+ candidates plus Merck collaboration intismeran, though shares rallied 65% YTD despite current analyst skepticism.
📅 Moderna is scheduled to report its first-quarter 2026 earnings on May 1, before the opening bell.
📉 Analysts expect sales of $223.5 million and a loss of $2.29 per share, showing improvement from the prior year.
💊 Sales will likely be driven primarily by two COVID-19 vaccines (Spikevax and mNexspike) with minimal revenue from the RSV vaccine (mResvia).
🌍 The EU approved Moderna’s mCombriax combination vaccine for COVID-19 and influenza earlier this month, adding to its portfolio.
💉 mCombriax builds on successful late-stage data for its standalone flu shot component which showed superior efficacy against GSK’s vaccine.
🧬 Investors will focus on updates regarding the commercialization timeline of mCombriax and the FDA resubmission status.
🔬 Moderna is developing more than 30 mRNA-based investigational candidates across various clinical stages, including cancer therapies.
🤝 A key pipeline candidate is intismeran autogene, a personalized cancer therapy developed in collaboration with Merck for multiple indications.
📊 Moderna has beaten earnings estimates in each of the trailing four quarters with an average surprise of 34.40%.
📈 Shares have rallied 65% year to date compared to the industry’s 1% decline.
⚠️ The company currently carries a Zacks Rank #3 and an Earnings ESP of -25.75%, suggesting analysts do not expect a beat this time.
Bullish Signals
- Moderna beat estimates by 18.85%, indicating strong performance ahead of Q1 2026 earnings.
- Company has achieved earnings beats in each of the trailing four quarters.
- Shares rallied 65% year to date, significantly outperforming industry decline.
- Moderna secured EU approval for mCombriax, expanding portfolio to four marketed products.
- Flu shot mRNA-1010 showed superior efficacy compared with GSK's approved vaccine.
- Moderna develops more than 30 mRNA-based candidates across various clinical stages.
- Intismeran autogene evaluated in three phase III studies for cancer therapy.
Risk Factors
- Competition from GSK and Pfizer limits RSV vaccine sales expectations.
- Analysts forecast earnings loss of $2.87 per share.
- Stock rallied 65% year to date, inflating valuations ahead of earnings.
- FDA resubmission concerns linger after mCombriax filing withdrawal.
- Earnings ESP at -25.75% lowers probability of beating estimates.
- Zacks Rank #3 indicates limited analyst confidence in stock.
- mCombriax faces commercialization uncertainty after efficacy data requests.
Bullish Signals
- Moderna beat earnings estimates by 18.85% in the last reported quarter, indicating strong performance ahead of its Q1 2026 earnings report on May 1.
- The company has achieved an impressive track record with earnings beats in each of the trailing four quarters and an average surprise of 34.40%.
- Moderna's shares have rallied 65% year to date, significantly outperforming the industry's 1% decline.
- Earlier this month, Moderna secured EU approval for mCombriax (mRNA-1083), expanding its portfolio to four marketed products including two COVID-19 vaccines and an RSV vaccine.
- The company's standalone flu shot, mRNA-1010, demonstrated superior efficacy compared with GSK's approved influenza vaccine, addressing previous concerns about mCombriax's flu component.
- Moderna is developing more than 30 mRNA-based investigational candidates across different stages of clinical studies targeting various indications, including cancer.
- Intismeran autogene, a personalized cancer therapy developed in collaboration with Merck MRK, is being evaluated in three pivotal phase III studies in melanoma and non-small cell lung cancer.
Risk Factors
- Moderna is facing stiff competition from GSK and Pfizer in the RSV vaccine market, leading to expectations of minimal product sales for mResvia.
- Analysts are projecting an earnings loss of $2.87 per share according to the Most Accurate Estimate, indicating ongoing profitability challenges.
- Moderna's stock has rallied 65% year to date despite industry-wide declines, potentially inflating valuations ahead of earnings.
- The company previously withdrew its initial mCombriax filing due to regulatory requests for additional efficacy data on the flu component, raising lingering concerns about FDA resubmission timelines.
- Moderna's Earnings ESP is currently negative at -25.75%, signaling a lower probability of beating estimates compared to competitors like Agenus and Inovio.
- The firm's Zacks Rank remains #3 (Hold), suggesting limited analyst confidence relative to top-rated peers with stronger buy recommendations.
- While the company has approved its fourth marketed product, mCombriax faces an uncertain path to commercialization following a voluntary withdrawal and subsequent efficacy concerns.
Moderna (MRNA) is scheduled to report its first-quarter 2026 earnings on May 1 before the opening bell. The company's last reported quarter saw earnings beat estimates by 18.85%, with Zacks Consensus Estimates for the upcoming quarter pegged at $223.5 million in sales and a loss of $2.29 per share, indicating improvement over the year-ago period. Revenue is expected to stem primarily from three marketed products: two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia), though product sales for the RSV vaccine are anticipated to be minimal due to stiff competition from established RSV vaccines by GSK and Pfizer.
Significant investor attention will focus on updates regarding Moderna's recent European Union approval for mCombriax, a combination vaccine for COVID-19 and influenza, which marks the company's fourth marketed product. The initial filing for mCombriax was withdrawn last year following regulatory requests for additional efficacy data on the flu component, an issue resolved with positive late-stage data in June 2025 showing Moderna's standalone flu shot mRNA-1010 demonstrated superior efficacy compared to GSK’s influenza vaccine. Management is expected to provide timelines for FDA resubmission and commercialization plans.
Beyond its current portfolio, investors will likely seek progress updates on Moderna's pipeline, which includes more than 30 mRNA-based investigational candidates targeting various indications such as cancer. A key focus will be intismeran autogene, a personalized cancer therapy being developed in collaboration with Merck (MRK), currently undergoing evaluation in three pivotal phase III studies for melanoma and non-small cell lung cancer, alongside mid-stage studies for bladder and renal cancers. Over the past four quarters, Moderna has consistently beaten earnings estimates, averaging a 34.40% surprise, outperforming the industry with shares rallying 65% year to date versus an industry decline of 1%. However, analysts note that Moderna currently carries a Zacks Rank #3 and an Earnings ESP of -25.75%, resulting in a negative outlook for an earnings beat this time around despite its strong recent performance history.
📅 Moderna reports Q1 2026 earnings May 1 ahead of opening bell.
💰 Revenue consensus $223.5M; EPS loss $2.29 improves year-over-year.
💉 Sales from COVID and RSV vaccines, though RSV outlook remains soft.
🔬 EU approved mCombriax flu vaccine after FDA resubmission focus.
📊 Shares up 65% YTD despite negative earnings surprise potential.
📅 Moderna is scheduled to report first-quarter 2026 earnings on May 1 before the opening bell.
📈 The company's last reported quarter saw earnings beat estimates by 18.85%, but this latest report does not predict a beat.
💰 Sales consensus estimate is pegged at $223.5 million, with earnings pinned at a loss of $2.29 per share, both showing improvement year-over-year.
💉 Product sales are expected to come from three marketed vaccines: two COVID-19 vaccines (Spikevax and mNexspike) and the RSV vaccine (mResvia).
⚠️ RSV vaccine sales outlook is soft due to stiff competition from GSK and Pfizer, leading to expectations of minimal product revenue for mResvia.
💊 Moderna secured EU approval for mCombriax, its first combination vaccine against COVID-19 and influenza, which marks the company's fourth marketed product.
🔬 The FDA resubmission timeline for mCombriax is expected to be a key focus after the filing was voluntarily withdrawn last year due to efficacy data requests.
⚖️ Moderna demonstrated superior efficacy for its standalone flu shot (mRNA-1010) compared to GSK's vaccine in late-stage data announced in June 2025.
🧬 The company has a pipeline of over 30 mRNA-based investigational candidates in various clinical stages targeting indications like cancer.
💊 Intismeran autogene, a personalized cancer therapy collaboration with Merck (MRK), is under evaluation in three pivotal phase III studies for melanoma and lung cancer.
📉 Year-to-date shares have rallied 65% against the industry's 1% decline, though current Earnings ESP stands at -25.75%.
🏆 Moderna has beaten earnings estimates for each of the trailing four quarters with an average surprise of 34.40%, but Zacks currently assigns a Rank #3 (Hold).
🚀 The article highlights Agenus and Inovio Pharmaceuticals as other stocks that meet specific criteria to potentially beat earnings expectations.
📊 Agenus (AGEN) has a +7.69% Earnings ESP and a Zacks Rank #1, with shares rising 30% year-to-date.
📉 Inovio (INO) shows a +3.33% Earnings ESP and a Zacks Rank #2, despite shares losing 33% year-to-date.
🔎 Readers are encouraged to use the Earnings ESP Filter to uncover other stocks with high odds of beating earnings before the report.
Bullish Signals
- Moderna to report Q1 2026 earnings on May 1 with sales and earnings improvements.
- Revenue from three marketed products including two COVID vaccines and one RSV vaccine.
- Secured EU approval for mCombriax, the first combo vaccine targeting COVID and flu.
- Standalone flu shot showed superior efficacy versus GSK approved influenza vaccine.
- Developing over 30 mRNA candidates across various clinical study stages.
- Intismeran autogene in three phase III studies for melanoma and lung cancer.
- Beat estimates four consecutive quarters with average surprise of 34.40%.
- Shares rallied 65% year to date versus industry decline.
Risk Factors
- Moderna holds Zacks Rank #3 Hold vs. peers' Strong Buy ratings.
- Earnings ESP negative at -25.75% for Q1 2026, likely missing estimates.
- Analysts forecast $2.87 loss/share; prior quarter beat by 18.85%.
- RSV vaccine mResvia faces stiff competition from GSK and Pfizer.
- mCombriax filing withdrawn after FDA requested more flu data.
Bullish Signals
- Moderna is scheduled to report first-quarter 2026 earnings on May 1 with both sales and earnings showing improvement over the year-ago period.
- The company earned from three marketed products, including two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia).
- Moderna recently secured EU approval for mCombriax, its first combination vaccine targeting both COVID-19 and influenza.
- The initial efficacy data for Moderna's standalone flu shot demonstrated superior performance compared with GSK's approved influenza vaccine.
- Moderna is developing more than 30 mRNA-based investigational candidates across various stages of clinical studies, including targets for cancer.
- Intismeran autogene, a personalized cancer therapy in partnership with Merck, is being evaluated in three pivotal phase III studies for melanoma and non-small cell lung cancer.
- Moderna's performance has been impressive over the past four quarters, beating estimates each time with an average surprise of 34.40%.
- Year to date, Moderna shares have rallied 65% against the industry's decline.
Risk Factors
- Moderna faces a Zacks Rank #3, indicating Hold status, compared to Strong Buy ratings given by analysts for other biotech peers like Agenus and Inovio.
- The Earnings ESP for Moderna is significantly negative at -25.75%, suggesting the company's earnings are likely to miss analyst expectations for Q1 2026.
- Analysts estimate a loss of $2.87 per share, which contrasts with the previous quarter's performance where the company beat estimates by 18.85%.
- The RSV vaccine mResvia is expected to have minimal product sales due to stiff competition from GSK and Pfizer's strong market foothold in that segment.
- The combination vaccine mCombriax had its initial filing voluntarily withdrawn last year after the FDA requested additional efficacy data for the flu component.
- Moderna currently carries a Zacks Rank #3, whereas peers Agenus and Inovio hold higher-ranked statuses of #1 Strong Buy and #2 Buy respectively.
Moderna (MRNA) is scheduled to release its first-quarter 2026 earnings report on May 1, ahead of the market open, following a streak of four consecutive quarters where it beat analyst estimates by an average of 34.40%. The Zacks Consensus Estimate projects sales of $223.5 million and a loss of $2.29 per share, both figures representing improvements over the year-ago period. Revenue is anticipated to derive primarily from two COVID-19 vaccines, Spikevax and mNexspike, as well as the RSV vaccine, mResvia. However, analysts expect minimal product sales for mResvia due to significant market competition from RSV vaccines produced by GSK and Pfizer.
Beyond established products, investors are likely to monitor commercialization updates for Moderna's fourth marketed product, mCombriax (mRNA-1083), which recently received EU approval as the first combination vaccine for active immunization against COVID-19 and influenza. This initiative follows the voluntary withdrawal of the initial filing in the previous year due to requests for additional efficacy data on the flu component; Moderna addressed this with positive late-stage data announced in June 2025, where its standalone flu shot, mRNA-1010, showed superior efficacy compared to GSK's approved influenza vaccine. The pipeline remains active with more than 30 mRNA-based investigational candidates, including the intismeran autogene personalized cancer therapy being developed in collaboration with Merck (MRK). This joint venture includes three pivotal phase III studies for melanoma and non-small cell lung cancer, alongside mid-stage evaluations for bladder and renal cancers.
Despite a historical track record of strong performance, analysts currently do not predict an earnings beat for this quarter, citing a negative Earnings ESP of -25.75%. The consensus estimate stands at a loss of $2.87 per share with Zacks tracking that figure at $2.29, and the company holds a Zacks Rank #3 (Hold). In contrast to Moderna's recent stock rally of 65% year-to-date against an industry decline, other biotech stocks such as Agenus (AGEN) and Inovio Pharmaceuticals (INO) are highlighted for having positive earnings ESPs and strong buy or hold ranks.
The provided content also references unrelated financial data from Merck & Co., Inc. (MRK), which reported a Q1 2026 adjusted loss of $1.28 per share, narrower than the consensus estimate of $1.51. Merck's revenue increased 5% year-over-year to $16.29 billion on a reported basis, driven significantly by its flagship product Keytruda, which generated $8.03 billion in sales, an 8% increase. These earnings were impacted by a $3.62 per share charge related to the acquisition of Cidara Therapeutics, while Keytruda sales beat consensus estimates by including $128 million in sales from its new subcutaneous formulation, Keytruda Qlex. All growth figures discussed regarding Merck exclude foreign exchange impacts.
📈 Moderna beats 4 quarters with avg 34.4% surprise, Zacks predicts $2.29 loss estimate.
💰 Q1 sales expected $223.5M from COVID-19 and RSV vaccines despite RSV competition.
🚀 Shares rallied 65% year-to-date vs 1% industry decline as EU approves new combo vaccine.
📅 Moderna is scheduled to report Q1 2026 earnings results on May 1, before the market opens.
📊 The company beat estimates by 18.85% in the previous reported quarter with improving sales and loss metrics.
💰 Analysts expect product sales of roughly $223.5 million, primarily driven by two COVID-19 vaccines and one RSV vaccine.
⚠️ Revenue from the RSV vaccine mResvia is projected to be minimal due to strong competition from GSK and Pfizer.
🔬 Moderna secured EU approval earlier this month for mCombriax, a new combination vaccine against COVID-19 and influenza.
💉 The initial filing for mCombriax was withdrawn previously but late-stage data showed superior efficacy of the standalone flu component mRNA-1010.
🧬 The company is developing over 30 investigational candidates across various clinical stages, including cancer therapies.
🤝 A key pipeline highlight is intismeran autogene, a personalized cancer therapy being evaluated in three pivotal phase III studies with Merck.
📈 Moderna has beaten earnings estimates for the trailing four consecutive quarters with an average surprise of 34.40%.
🚀 Shares have rallied 65% year-to-date while the broader industry has seen a 1% decline.
⚙️ The Zacks Consensus Estimate predicts a loss of $2.29 per share for this quarter.
📉 Analysis indicates a probability of earnings miss based on current Earnings ESP metrics and stock rank.
Bullish Signals
- Moderna beat earnings estimates by 34.40% over four quarters.
- Shares rallied 65% year-to-date while industry fell 1%.
- EU approved mCombriax, Moderna's fourth marketed product.
- Flu shot mRNA-1010 outperformed GSK vaccine in late-stage data.
- Pipeline has 30+ mRNA candidates across clinical stages.
- Autogene therapy evaluated in three pivotal melanoma/lung cancer studies.
Risk Factors
- Losses deepen to $2.87/share per The Most Accurate Estimate.
- Earnings ESP at -25.75% signals high miss probability.
- RSV vaccine faces stiff competition from GSK and Pfizer.
- Revenue sustainability threatened by reliance on COVID-19 vaccines.
- mCombriax filing withdrawn previously over FDA efficacy data requests.
- Zacks Rank #3 Hold is less favorable than Strong Buy #1.
- mCombriax requires FDA resubmission without guaranteed timeline.
Bullish Signals
- Moderna earned strong momentum over the past four quarters, beating earnings estimates each time with an average surprise of 34.40%.
- Year-to-date, Moderna's shares have rallied 65% against the industry's 1% decline.
- Moderna secured approval in the EU for mCombriax (mRNA-1083), marking it as the fourth marketed product in the company's portfolio.
- Moderna's standalone flu shot, mRNA-1010, demonstrated superior efficacy compared with GSK's approved influenza vaccine based on late-stage data announced in June 2025.
- The pipeline includes more than 30 mRNA-based investigational candidates across different stages of clinical studies, including cancer indications.
- Moderna is evaluating intismeran autogene, a personalized cancer therapy developed with Merck MRK, in three pivotal phase III studies targeting melanoma and non-small cell lung cancer.
Risk Factors
- Operating losses are projected to deepen with a Zacks Consensus Estimate of a $2.29 per share loss for Q1, though The Most Accurate Estimate is pegged at an even deeper loss of $2.87.
- The Earnings ESP stands at -25.75%, indicating high probability of missing analyst expectations and potential stock underperformance.
- Moderna's RSV vaccine mResvia faces a softer outlook due to stiff competition from GSK and Pfizer, who have established strong footholds in the market.
- A significant portion of product sales is expected to come from COVID-19 vaccines, raising concerns about post-pandemic revenue sustainability and demand fatigue.
- The initial filing for mCombriax was voluntarily withdrawn last year after the agency requested additional efficacy data for the flu component, indicating previous regulatory hurdles.
- Moderna currently carries a Zacks Rank #3 (Hold), which is less favorable compared to the Strong Buy (#1) or Buy (#2) recommendations preferred by investors.
- The company's standalone flu shot demonstrated superior efficacy in June 2025, but mCombriax integration still requires FDA resubmission without a guaranteed timeline.
